Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Takeda’s zasocitinib demonstrates positive results in plaque psoriasis

Around 64 million people worldwide live with psoriasis

- PMLiVE

NanoSyrinx appoints Thomas J Farrell as CEO

Farrell was previously founder and CEO of two NASDAQ-listed companies

- PMLiVE

AbbVie reaches agreement for affordable prescription drugs with US government

The pharma company has also pledged a $100bn investment in US infrastructure over the next decade

- PMLiVE

VML Health appoints Nadine Leonard as Global Chief Solutions & Innovation Officer

Leonard was previously Therapeutic Area Lead for Pfizer’s oncology branch

- PMLiVE

Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity

Obesity affects approximately 15 million people in the UK

- PMLiVE

Enhanced Genomics appoints Katerina Leftheris to Board of Directors

Leftheris has held senior scientific roles at Bristol Myers Squibb and Celgene

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

- PMLiVE

BMS announces affordable drug price agreement with US government

The company will provide Eliquis, its oral blood thinner, free of charge to Medicaid

- PMLiVE

Gilead appoints Keeley Wettan as Executive VP, General Counsel, Legal & Compliance

Wettan has served at Gilead for over 14 years

- PMLiVE

The Heart and Mouth Connection Every Woman Needs to Know

For decades, modern medicine has treated the mouth and the body as separate entities. But for Dr. Nieca Goldberg, a renowned cardiologist, and Dr. Maria Ryan, Chief Clinical Officer at...

Medscape Education

- PMLiVE

Lilly announces acquisition of Ventyx Biosciences for around $1.2bn

Multiple Ventyx drugs are currently in phase 2 development for inflammatory disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links